These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1068 related items for PubMed ID: 22194217

  • 1. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.
    Acta Neurol Scand; 2012 Nov 02; 126(5):306-14. PubMed ID: 22107083
    [Abstract] [Full Text] [Related]

  • 6. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
    Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B.
    PLoS One; 2014 Nov 02; 9(3):e91098. PubMed ID: 24625687
    [Abstract] [Full Text] [Related]

  • 7. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan 02; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 8. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr 02; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 9. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C.
    Mult Scler; 2012 Jan 02; 18(1):64-71. PubMed ID: 21828195
    [Abstract] [Full Text] [Related]

  • 10. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 02; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 11. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P.
    Mult Scler; 2012 Dec 10; 18(12):1760-7. PubMed ID: 22570359
    [Abstract] [Full Text] [Related]

  • 13. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S, Hassinger S, Lindquist JA, Sailer M.
    Mult Scler; 2011 Jul 10; 17(7):851-66. PubMed ID: 21561957
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 10; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 15. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 16. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 10; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 17. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
    Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.
    Ann Neurol; 2013 Jan 10; 73(1):95-103. PubMed ID: 23378325
    [Abstract] [Full Text] [Related]

  • 18. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS.
    Mult Scler; 2004 Oct 10; 10(5):511-20. PubMed ID: 15471366
    [Abstract] [Full Text] [Related]

  • 19. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
    Neurology; 2012 Apr 03; 78(14):1069-78. PubMed ID: 22442431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.